vs

Side-by-side financial comparison of CROWN CRAFTS INC (CRWS) and RECURSION PHARMACEUTICALS, INC. (RXRX). Click either name above to swap in a different company.

RECURSION PHARMACEUTICALS, INC. is the larger business by last-quarter revenue ($35.5M vs $20.7M, roughly 1.7× CROWN CRAFTS INC). CROWN CRAFTS INC runs the higher net margin — 7.3% vs -304.2%, a 311.5% gap on every dollar of revenue. On growth, RECURSION PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (681.7% vs -11.3%). CROWN CRAFTS INC produced more free cash flow last quarter ($2.3M vs $-47.3M). Over the past eight quarters, RECURSION PHARMACEUTICALS, INC.'s revenue compounded faster (60.5% CAGR vs -6.7%).

Crown Crafts is a publicly held American company headquartered in Gonzales, Louisiana. The company designs, markets and distributes infant, toddler and juvenile consumer products. Its stock is traded on the NASDAQ Capital Market under the ticker symbol "CRWS".

Recursion Pharmaceuticals is a clinical-stage biotechnology company that combines artificial intelligence and large-scale high-throughput biological experimentation to discover and develop innovative therapies for rare diseases, oncology, inflammatory disorders, and other areas of unmet medical need. It primarily operates in North America and partners with global biopharmaceutical firms to advance its robust therapeutic pipeline.

CRWS vs RXRX — Head-to-Head

Bigger by revenue
RXRX
RXRX
1.7× larger
RXRX
$35.5M
$20.7M
CRWS
Growing faster (revenue YoY)
RXRX
RXRX
+693.0% gap
RXRX
681.7%
-11.3%
CRWS
Higher net margin
CRWS
CRWS
311.5% more per $
CRWS
7.3%
-304.2%
RXRX
More free cash flow
CRWS
CRWS
$49.7M more FCF
CRWS
$2.3M
$-47.3M
RXRX
Faster 2-yr revenue CAGR
RXRX
RXRX
Annualised
RXRX
60.5%
-6.7%
CRWS

Income Statement — Q3 FY2026 vs Q4 FY2025

Metric
CRWS
CRWS
RXRX
RXRX
Revenue
$20.7M
$35.5M
Net Profit
$1.5M
$-108.1M
Gross Margin
23.5%
59.8%
Operating Margin
-0.5%
-304.8%
Net Margin
7.3%
-304.2%
Revenue YoY
-11.3%
681.7%
Net Profit YoY
69.1%
39.6%
EPS (diluted)
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CRWS
CRWS
RXRX
RXRX
Q4 25
$20.7M
$35.5M
Q3 25
$23.7M
$5.2M
Q2 25
$15.5M
$19.2M
Q1 25
$23.2M
$14.7M
Q4 24
$23.4M
$4.5M
Q3 24
$24.5M
$26.1M
Q2 24
$16.2M
$14.4M
Q1 24
$13.8M
Net Profit
CRWS
CRWS
RXRX
RXRX
Q4 25
$1.5M
$-108.1M
Q3 25
$1.2M
$-162.3M
Q2 25
$-1.1M
$-171.9M
Q1 25
$-10.8M
$-202.5M
Q4 24
$893.0K
$-178.9M
Q3 24
$860.0K
$-95.8M
Q2 24
$-322.0K
$-97.5M
Q1 24
$-91.4M
Gross Margin
CRWS
CRWS
RXRX
RXRX
Q4 25
23.5%
59.8%
Q3 25
27.7%
-183.8%
Q2 25
22.7%
-4.9%
Q1 25
18.3%
-48.0%
Q4 24
26.1%
-181.4%
Q3 24
28.4%
53.7%
Q2 24
24.5%
36.2%
Q1 24
19.1%
Operating Margin
CRWS
CRWS
RXRX
RXRX
Q4 25
-0.5%
-304.8%
Q3 25
7.9%
-3327.6%
Q2 25
-7.7%
-916.8%
Q1 25
-60.7%
-1297.9%
Q4 24
7.3%
-4042.4%
Q3 24
6.2%
-377.1%
Q2 24
-1.8%
-697.4%
Q1 24
-698.4%
Net Margin
CRWS
CRWS
RXRX
RXRX
Q4 25
7.3%
-304.2%
Q3 25
4.9%
-3135.3%
Q2 25
-7.1%
-894.2%
Q1 25
-46.4%
-1373.3%
Q4 24
3.8%
-3935.5%
Q3 24
3.5%
-367.5%
Q2 24
-2.0%
-676.6%
Q1 24
-662.4%
EPS (diluted)
CRWS
CRWS
RXRX
RXRX
Q4 25
$-0.17
Q3 25
$-0.36
Q2 25
$-0.10
$-0.41
Q1 25
$-0.50
Q4 24
$-0.56
Q3 24
$-0.34
Q2 24
$-0.03
$-0.40
Q1 24
$-0.39

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CRWS
CRWS
RXRX
RXRX
Cash + ST InvestmentsLiquidity on hand
$2.4M
$743.3M
Total DebtLower is stronger
$9.6M
Stockholders' EquityBook value
$39.2M
$1.1B
Total Assets
$76.1M
$1.5B
Debt / EquityLower = less leverage
0.01×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CRWS
CRWS
RXRX
RXRX
Q4 25
$2.4M
$743.3M
Q3 25
$810.0K
$659.8M
Q2 25
$227.0K
$525.1M
Q1 25
$521.0K
$500.5M
Q4 24
$1.1M
$594.4M
Q3 24
$2.0M
$427.6M
Q2 24
$1.1M
$474.3M
Q1 24
$296.3M
Total Debt
CRWS
CRWS
RXRX
RXRX
Q4 25
$9.6M
Q3 25
$11.9M
Q2 25
$14.2M
Q1 25
$16.4M
Q4 24
$19.0M
Q3 24
$20.5M
Q2 24
$22.9M
Q1 24
Stockholders' Equity
CRWS
CRWS
RXRX
RXRX
Q4 25
$39.2M
$1.1B
Q3 25
$38.4M
$1.0B
Q2 25
$37.9M
$919.1M
Q1 25
$39.6M
$933.9M
Q4 24
$51.1M
$1.0B
Q3 24
$50.8M
$524.6M
Q2 24
$50.7M
$584.4M
Q1 24
$401.2M
Total Assets
CRWS
CRWS
RXRX
RXRX
Q4 25
$76.1M
$1.5B
Q3 25
$77.5M
$1.4B
Q2 25
$76.0M
$1.3B
Q1 25
$81.2M
$1.3B
Q4 24
$98.7M
$1.4B
Q3 24
$99.3M
$726.5M
Q2 24
$76.4M
$775.9M
Q1 24
$557.8M
Debt / Equity
CRWS
CRWS
RXRX
RXRX
Q4 25
0.01×
Q3 25
0.01×
Q2 25
0.02×
Q1 25
0.02×
Q4 24
0.02×
Q3 24
0.04×
Q2 24
0.04×
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CRWS
CRWS
RXRX
RXRX
Operating Cash FlowLast quarter
$2.7M
$-46.1M
Free Cash FlowOCF − Capex
$2.3M
$-47.3M
FCF MarginFCF / Revenue
11.3%
-133.1%
Capex IntensityCapex / Revenue
1.7%
3.5%
Cash ConversionOCF / Net Profit
1.78×
TTM Free Cash FlowTrailing 4 quarters
$9.1M
$-378.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CRWS
CRWS
RXRX
RXRX
Q4 25
$2.7M
$-46.1M
Q3 25
$-845.0K
$-117.4M
Q2 25
$5.2M
$-76.4M
Q1 25
$2.8M
$-132.0M
Q4 24
$-36.0K
$-115.4M
Q3 24
$-983.0K
$-59.2M
Q2 24
$8.0M
$-82.2M
Q1 24
$-102.3M
Free Cash Flow
CRWS
CRWS
RXRX
RXRX
Q4 25
$2.3M
$-47.3M
Q3 25
$-1.0M
$-117.6M
Q2 25
$5.2M
$-79.6M
Q1 25
$2.6M
$-133.8M
Q4 24
$-220.0K
$-116.7M
Q3 24
$-1.2M
$-63.8M
Q2 24
$7.7M
$-83.4M
Q1 24
$-109.0M
FCF Margin
CRWS
CRWS
RXRX
RXRX
Q4 25
11.3%
-133.1%
Q3 25
-4.3%
-2272.5%
Q2 25
33.4%
-413.9%
Q1 25
11.3%
-907.4%
Q4 24
-0.9%
-2567.7%
Q3 24
-4.8%
-244.6%
Q2 24
47.7%
-578.5%
Q1 24
-789.9%
Capex Intensity
CRWS
CRWS
RXRX
RXRX
Q4 25
1.7%
3.5%
Q3 25
0.7%
4.7%
Q2 25
0.6%
16.4%
Q1 25
0.9%
12.4%
Q4 24
0.8%
28.6%
Q3 24
0.8%
17.5%
Q2 24
1.8%
8.2%
Q1 24
48.2%
Cash Conversion
CRWS
CRWS
RXRX
RXRX
Q4 25
1.78×
Q3 25
-0.73×
Q2 25
Q1 25
Q4 24
-0.04×
Q3 24
-1.14×
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons